Evidence method
Level · gp.fundamentals.capex_revenue_ratio
17.25% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CPIX · Dec 31, 2017
CUMBERLAND PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-18-003034General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-34.86% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-20.00% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
421.12% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
-360.66% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-255.08% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
243.84% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
69.69% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History61 statesSelf-history eligible
Sep 30, 20217/7 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20264/4 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.27%
- Current
- 17.25%
- Delta
- 16.98%
- Previous
- 8.87%
- Current
- -34.86%
- Delta
- -43.72%
- Previous
- 27.36%
- Current
- -20.00%
- Delta
- -47.36%
- Previous
- 52.31%
- Current
- 421.12%
- Delta
- 368.80%
- Previous
- 80.65%
- Current
- -360.66%
- Delta
- -441.31%
- Previous
- -7.50%
- Current
- -255.08%
- Delta
- -247.59%
- Previous
- 8.42%
- Current
- 243.84%
- Delta
- 235.41%
- Previous
- 2.66%
- Current
- 69.69%
- Delta
- 67.03%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CPIX Fundamental State →Has State · CUMBERLAND PHARMACEUTICALS INC →Transitioned To · CPIX Fundamental State →Transitioned To · CPIX CAPEX_INTENSITY_INCREASED →Transitioned To · CPIX CASH_GENERATION_DECREASED →Transitioned To · CPIX GROWTH_DECREASED →Transitioned To · CPIX INVENTORY_PRESSURE_INCREASED →Transitioned To · CPIX MARGIN_DECREASED →Transitioned To · CPIX PROFITABILITY_DECREASED →Transitioned To · CPIX R_AND_D_INTENSITY_INCREASED →Transitioned To · CPIX SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.